Trial Profile
Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 23 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Allogeneic stem cell therapy; Antithymocyte globulin; Busulfan; Clofarabine; Mycophenolate mofetil; Mycophenolate mofetil; Rituximab; Tacrolimus; Tacrolimus
- Indications B-cell lymphoma; Graft-versus-host disease; Hodgkin's disease; Lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 18 Nov 2021 Planned End Date changed from 1 May 2022 to 31 May 2024.
- 18 Nov 2021 Planned primary completion date changed from 1 May 2021 to 31 May 2024.
- 18 Nov 2021 Status changed from recruiting to active, no longer recruiting.